Zacks Investment Research · Jul 6, 2023
Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY
Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.
SG
NASDAQ · SGTX
Sigilon Therapeutics, Inc.
Healthcare · Biotechnology
$22.47
Down-$0.59 (-2.56%)
Updated Aug 25, 2026, 5:46 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 56.22M
- P/E ratio
- -16.76
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 81.88K
- Avg. volume
- 128.32K
Price performance
SGTX price history
1M range · 0 trading sessions · Daily adjusted prices
SGTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest SGTX news
The latest Smart Investors Daily articles mentioning SGTX.
Stock researchCompany · Overview
SGTX research
Overview
Company profile and research snapshot.
Company profile
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 5, 2023 | Canaccord Genuity | Buy | — |
| Jul 3, 2023 | Morgan Stanley | Equal-Weight | — |
| Jun 30, 2023 | Morgan Stanley | Equal-Weight | — |
| Jun 30, 2023 | BTIG | Neutral | — |
| May 26, 2023 | Morgan Stanley | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Zacks Investment Research · Jun 30, 2023
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.
MarketWatch · Jun 29, 2023
Sigilon Therapeutics’ stock soars 550% after Eli Lilly agrees to acquire company
Deal is focused on new cell therapies to improve diabetes care.
GlobeNewswire Inc. · May 22, 2023
Sigilon Announces Reverse Stock Split of Common Stock
CAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock. Sigilon stockholders approved an amendment to Sigilon’s Fifth Amended and Restated Certificate of Incorporation to effect the reverse stock split at Sigilon’s Annual Meeting of Stockholders held on May 19, 2023. The reverse stock split is intended to increase the per share trading price of Sigilon’s common stock to enable Sigilon to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market. Sigilon expects that upon the opening of trading on May 23, 2023, its common stock will trade on the Nasdaq Global Select Market on a split-adjusted basis under the current trading symbol “SGTX” and the CUSIP number 82657L206.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
